These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 807757)

  • 1. [Amikacin treatment of septicemia due to gentamicin-resistant gram-negative bacilli (author's transl)].
    Tomioka H; Kobayashi Y; Tamatani S; Morishita T; Hasegawa Y
    Jpn J Antibiot; 1975 Jun; 28(3):305-8. PubMed ID: 807757
    [No Abstract]   [Full Text] [Related]  

  • 2. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
    Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antibacterial activity of gentamicin, tobramycin, amikacin, and sisomicin in vitro (author's transl)].
    Skalova R; Hajsig D; Babić I; Mostovac D
    Lijec Vjesn; 1978 Nov; 100(11):708-10. PubMed ID: 107386
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of Pseudomonas aeruginosa pneumonia with amikacin (author's transl)].
    Izawa T; Katakura K
    Jpn J Antibiot; 1979 Apr; 32(4):532-4. PubMed ID: 110964
    [No Abstract]   [Full Text] [Related]  

  • 5. Experimental infection in rabbits evoked by Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae treated with gentamicin, amikacin and sisomicin.
    Jeljaszewicz J; Włodarczak K; Bis W; Kazanowski A; Kuzniewski P; Molska J
    Zentralbl Bakteriol A; 1980 Aug; 247(3):347-52. PubMed ID: 6999802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli].
    Nicoletti G; Russo G; Toscano MA; Gismondo MR
    Boll Ist Sieroter Milan; 1979 Jan; 57(6):713-7. PubMed ID: 121911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of seven distinct carbapenemase-producing Gram-negative organisms from a single patient.
    Creighton J; Heffernan H; Howard J
    J Antimicrob Chemother; 2017 Jan; 72(1):317-319. PubMed ID: 27621176
    [No Abstract]   [Full Text] [Related]  

  • 8. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories.
    Barry AL; Thornsberry C; Jones RN
    J Clin Microbiol; 1981 May; 13(5):1000-3. PubMed ID: 6787072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic experience of Proteus morganii septicemia with amikacin (author's transl)].
    Tomioka H; Kobayashi Y; Shigeta Y
    Jpn J Antibiot; 1977 Aug; 30(8):593-5. PubMed ID: 909148
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative effectiveness of gentamycin and other antibiotics in experiment].
    Navashin SM; Fomina IP; Kuznetsova SM
    Antibiotiki; 1969 Aug; 14(8):716-21. PubMed ID: 4314051
    [No Abstract]   [Full Text] [Related]  

  • 13. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M; Bodey GP
    Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.
    Leonard JM; McGee ZA; Alford RH
    Arch Intern Med; 1978 Feb; 138(2):201-5. PubMed ID: 415674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ; Simberkoff MS; Rahal JJ
    J Antimicrob Chemother; 1985 Aug; 16(2):227-34. PubMed ID: 3934125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas].
    Moreva TV; Anisimova LA; Erova TE; Boronin AM
    Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical experience with amikacin for respiratory infections due to gentamicin-resistant bacteria (author's transl)].
    Ito T
    Jpn J Antibiot; 1978 Jul; 31(7):346-52. PubMed ID: 691256
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)].
    Drugeon HB; Courtieu AL
    Ann Microbiol (Paris); 1979 Apr; 130A(3):331-43. PubMed ID: 114083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.